ArticleBreast cancer (Dove Medical Press)2025
Clinical Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte Index (CALLY) in Patients with Stage III Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Deciphering the potential of the C-reactive protein-albumin-lymphocyte index as a prognostic biomarker in malignancy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Diagnostic value of C-reactive protein-albumin-lymphocyte index in breast cancer cases.Frontiers in oncology · 2026Article
- Association of Pre-treatment CALLY Index With Pathological Response to Neoadjuvant Chemotherapy in Rectal Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the relationship between the C-reactive protein-albumin-lymphocyte index (CALLY) and clinicopathological characteristics, as well as its prognostic value in stage III breast cancer patients. Methods: A retrospective analysis was conducted on the clinicopathological data of 187 stage III breast cancer patients who were treated in our hospital from 2010 to 2015. The optimal cut-off value for CALLY index was determined by ROC curve. Chi-square tests and Fisher's exact tests were used for intergroup analysis. Survival curves were plotted using Kaplan-Meier method, and comparisons between groups were made using Log Rank test. Univariate and multivariate analyses were performed using the COX regression model. A nomogram prediction model was constructed based on the results of multivariate analysis and validated using the concordance index (C-index), calibration curves, and decision curve analysis (DCA). Results: According to ROC curve, the optimal cut-off value for CALLY was determined to be 0.10, dividing the patients into a low CALLY group (54 patients) and a high CALLY group (133 patients). CALLY was identified as a potential independent prognostic factor for stage III breast cancer patients. Patients with high CALLY values had longer survival time than those with low CALLY values (DFS: Conclusion: CALLY index is a potential independent prognostic factor for stage III breast cancer patients. It provides new insights and methods for clinical diagnosis and treatment of breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.